Sari Iltanen

Sari Iltanen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sari Iltanen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Merja Ashorn

    Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland

    7 shared publications
  • Sara Ashorn

    Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo Ylpön katu 34, 33014, Tampere, Finland

    5 shared publications
  • Immo Rantala

    ŧ Department of Pathology, Tampere University Hospital, Tampere

    3 shared publications
  • Jonathan Braun

    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

    3 shared publications
  • Katri Kaukinen

    Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital

    3 shared publications
  • Markku Mäki

    Hämeenlinna Central Hospital, Hämeenlinna, Finland

    3 shared publications

Latest Publications

  • Microbial Biomarkers in Patients with Nonresponsive Celiac Disease

    by Liisa Viitasalo, Kalle Kurppa, Merja Ashorn, Päivi Saavalainen, Heini Huhtala, Sara Ashorn, Markku Mäki, Tuire Ilus, Katri Kaukinen, Sari Iltanen

    In nonresponsive celiac disease (NRCD), the symptoms and duodenal damage persist despite a gluten-free diet. Celiac disease patients with persistent symptoms are found to have a dysbiotic microbiota. We thus hypothesized that increased seroreactivity to the serum gluten-sensitive microbial antibodies Saccharomyces cerevisiae (ASCA), Pseudomonas fluorescens-associated sequence (I2), and Bacteroides caccae TonB-linked outer membrane protein (OmpW) is associated with NRCD.


  • Early Microbial Markers of Celiac Disease

    by Liisa Viitasalo, Laura Niemi, Merja Ashorn, Sara Ashorn, Jonathan Braun, Heini Msc Huhtala, Pekka Collin, Markku Mäki, Katri Kaukinen, Kalle Kurppa, et al.

    Background and Goals: Seroreactivity against the Saccharomyces cerevisiae (ASCA), Pseudomonas fluorescens-associated sequence (I2), and Bacteroides caccae TonB-linked outer membrane protein (OmpW) has been detected in celiac disease patients with small-bowel mucosal atrophy. Levels of these antibodies decrease during a gluten-free diet, but their functions and time of appearance in celiac disease are not known. We aimed to search for evidence of possible microbial targets of the immune responses in the early-stage celiac disease patients who showed normal small-bowel mucosal architecture at the time of the first investigations, but later on a gluten-containing diet developed mucosal atrophy. Materials and Methods: Forty-four cases with proven early-stage celiac disease and normal mucosal morphology were enrolled. Patients’ sera were tested for celiac disease antibodies against tissue transglutaminase (tTG-ab), endomysium, and for microbial antibodies against I2, OmpW, and ASCA IgG and IgA isotypes in both at the time of diagnosis and while on a gluten-free diet. Results: Thirty-four (77%) of 44 patients with early-stage celiac disease had elevated serum antibodies to one or more of the antibodies ASCA, I2, and OmpW. Furthermore, 5 of 6 cases negative for both tTG-ab and endomysium showed positivity for the microbial markers. Seroreactivity to ASCA IgA, ASCA IgG, and OmpW decreased significantly during gluten-free diet. Conclusions: Seroreactivity to different microbial antigens is evident already in patients with early-stage celiac disease. ASCA antibodies seem to be gluten-dependent. The results indicate that the microbial targets might have a role in the early development of celiac disease.


  • Open Access

    Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease

    by Sara Ashorn, Teemu Honkanen, Kaija-Leena Kolho, Merja Ashorn, Tuuli Välineva, Bo Wei, Jonathan Braun, Immo Rantala, Tiina Luukkaala, Sari Iltanen

    Background. Noninvasive, sensitive, and specific tools for early identification of chronic inflammatory bowel disease (IBD) are needed for clinical pra


    • 1 January 2009
      • Vol. 125  (17) , 1849-56

    [Chronic inflammatory bowel diseases in children and adolescents].

    by Merja Ashorn, Sari Iltanen, Kaija-Leena Kolho

    Chronic inflammatory bowel diseases in children and adolescents Inflammatory bowel disease (IBD) is further increasing in children and adolescents in most Western countries including Finland. The etiologic factors of IBD and possible triggers have remained unclear. The clinical picture in paediatric IBD is more aggressive than in adults and operative intervention is common. Medical therapy is basically in line with the therapy used in adult patients. Optimal treatment is crucial in order to support normal growth and pubertal development. New serological and fecal analyses enhance the diagnostic accuracy and help the screening of the disease. The impact of IBD into the quality of life and psychosocial health has to be considered especially in severe cases.

  • Serological Responses to Microbial Antigens in Celiac Disease Patients During a Gluten-Free Diet

    by Sara Ashorn, Tuuli Välineva, Katri Kaukinen, Merja Ashorn, Jonathan Braun, Hanna Raukola, Immo Rantala, Pekka Collin, Markku Mäki, Tiina Luukkaala, et al.

    Immunoglobulin A (IgA) autoantibodies to tissue transglutaminase (tTG) are commonly used for screening and diagnosing of celiac disease (CD). Seroreactivity for anti-Saccharomyces cerevisiae antibody (ASCA) and bacterial antigens have also been detected in CD patients. The aim of this study was to examine prospectively serologic responses to microbial targets in adult CD patients at the time of diagnosis and during a gluten-free diet (GFD). Further, we wanted to evaluate whether these serologic specificities could provide new tools for the follow-up of CD patients.


  • Elevated Serum Anti-Saccharomyces cerevisiae, Anti-I2 and Anti-OmpW Antibody Levels in Patients with Suspicion of Celiac Disease

    by Sara Ashorn, Hanna Raukola, Tuuli Välineva, Merja Ashorn, Bo Wei, Jonathan Braun, Immo Rantala, Katri Kaukinen, Tiina Luukkaala, Pekka Collin, et al.

    Expression of anti-Saccharomyces cerevisiae antibodies (ASCA) identifies patients and individuals at risk for Crohn’s disease and has also been reported in 40–60% of celiac disease (CD) cases, suggesting a role of host response to enteric microbiota in the development of inflammatory lesions. In this prospective study in patients with suspicion of CD, we evaluate the frequency and association of ASCA to serological responses for other host microbial targets formally associated with Crohn’s disease, including the Pseudomonas fluorescens associated sequence I2 and a Bacteroides caccae TonB-linked outer membrane protein, OmpW.


  • Serological markers in gut inflammationȁCan endoscopies be avoided in paediatric patients?

    by Sari K. Iltanen, Merja Ashorn, Anu Mustila, Anna-Maija Haapala, Tarja Ruuska